Matritech regulatory update

NMPS submitted additional information requested by the FDA concerning two subgroups in its clinical trial of the NMP22 diagnostic kit for bladder cancer. Last month, the agency sent the company an approvable letter, but also requested more information about women and African Americans in the trial. ...